Overview

Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation

Status:
Unknown status

Trial end date:
2018-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe a new scheme can achieve is the same as the traditional scheme of the effect of preventing hepatitis B recurrence.

Phase:

Phase 4

Details

Lead Sponsor:

Third Affiliated Hospital, Sun Yat-Sen University

Treatments:

Antibodies
Entecavir
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin